Search Results - "Catcott, Kalli C"

Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates by Duvall, Jeremy R., Thomas, Joshua D., Bukhalid, Raghida A., Catcott, Kalli C., Bentley, Keith W., Collins, Scott D., Eitas, Timothy, Jones, Brian D., Kelleher, Eugene W., Lancaster, Kelly, Protopopova, Marina, Ray, Soumya S., Ter-Ovanesyan, Elena, Xu, Ling, Yang, Liping, Zurita, Jeffrey, Damelin, Marc, Toader, Dorin, Lowinger, Timothy B.

“…While STING agonists have proven to be effective preclinically as anti-tumor agents, these promising results have yet to be translated in the clinic. A STING…”
Get full text

Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses by Malli Cetinbas, Naniye, Monnell, Travis, Soomer-James, Jahna, Shaw, Pamela, Lancaster, Kelly, Catcott, Kalli C., Dolan, Melissa, Mosher, Rebecca, Routhier, Caitlin, Chin, Chen-Ni, Toader, Dorin, Duvall, Jeremy, Bukhalid, Raghida, Lowinger, Timothy B., Damelin, Marc

“…Activating interferon responses with STING agonists (STINGa) is a current cancer immunotherapy strategy, and therapeutic modalities that enable tumor-targeted…”
Get full text

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer by Toader, Dorin, Fessler, Shawn P, Collins, Scott D, Conlon, Patrick R, Bollu, Reddy, Catcott, Kalli C, Chin, Chen-Ni, Dirksen, Anouk, Du, Bingfan, Duvall, Jeremy R, Higgins, Stacy, Kozytska, Mariya V, Bellovoda, Kamela, Faircloth, Chelsey, Lee, David, Li, Fu, Qin, Liuliang, Routhier, Caitlin, Shaw, Pamela, Stevenson, Cheri A, Wang, Jason, Wongthida, Phonphimon, Ter-Ovanesyan, Elena, Ditty, Elizabeth, Bradley, Stephen P, Xu, Ling, Yin, Mao, Yurkovetskiy, Aleksandr V, Mosher, Rebecca, Damelin, Marc, Lowinger, Timothy B

“…Antibody-drug conjugates (ADCs) achieve targeted drug delivery to a tumor and have demonstrated clinical success in many tumor types. The activity and safety…”
Get full text

Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios by Clardy, Susan M, Uttard, Alex, Du, Bingfan, Catcott, Kalli C, Lancaster, Kelly L, Ditty, Elizabeth, Sadowsky, Jack, Zurita, Jeffrey, Malli, Naniye, Qin, LiuLiang, Bradley, Stephen P, Avocetien, Kenneth, Carter, Tyler, Kim, Dokyong, Nazzaro, Mark, Xu, Ling, Pillow, Thomas H, Zacharias, Neelie T, Lewis, Gail D, Rowntree, Rebecca K, Iyengar, Radha, Lee, David H, Damelin, Marc, Toader, Dorin, Lowinger, Timothy B

“…Key defining attributes of an antibody-drug conjugate (ADC) include the choice of the targeting antibody, linker, payload, and the drug-to-antibody ratio…”
Get more information

Identifying Unknown Enzyme–Substrate Pairs from the Cellular Milieu with Native Mass Spectrometry by Catcott, Kalli C., Yan, Jing, Qu, Wanlu, Wysocki, Vicki H., Zhou, Zhaohui Sunny

“…The enzyme–substrate complex is inherently transient, rendering its detection difficult. In our framework designed for bisubstrate systems—isotope‐labeled,…”
Get full text

Cover Picture: Identifying Unknown Enzyme–Substrate Pairs from the Cellular Milieu with Native Mass Spectrometry (ChemBioChem 7/2017) by Catcott, Kalli C., Yan, Jing, Qu, Wanlu, Wysocki, Vicki H., Zhou, Zhaohui Sunny

“…The cover picture shows a new approach to identifying enzyme–substrate pairs. The top panel shows a typical catalytic cycle of an enzyme, in which the enzyme…”
Get full text

Capturing Unknown Substrates via in Situ Formation of Tightly Bound Bisubstrate Adducts: S‑Adenosyl-vinthionine as a Functional Probe for AdoMet-Dependent Methyltransferases by Qu, Wanlu, Catcott, Kalli C, Zhang, Kun, Liu, Shanshan, Guo, Jason J, Ma, Jisheng, Pablo, Michael, Glick, James, Xiu, Yuan, Kenton, Nathaniel, Ma, Xiaoyu, Duclos, Richard I, Zhou, Zhaohui Sunny

“…Identifying an enzyme’s substrates is essential to understand its function, yet it remains challenging. A fundamental impediment is the transient interactions…”
Get full text

Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers by Bialucha, Carl U, Collins, Scott D, Li, Xiao, Saxena, Parmita, Zhang, Xiamei, Dürr, Clemens, Lafont, Bruno, Prieur, Pierric, Shim, Yeonju, Mosher, Rebecca, Lee, David, Ostrom, Lance, Hu, Tiancen, Bilic, Sanela, Rajlic, Ivana Liric, Capka, Vladimir, Jiang, Wei, Wagner, Joel P, Elliott, GiNell, Veloso, Artur, Piel, Jessica C, Flaherty, Meghan M, Mansfield, Keith G, Meseck, Emily K, Rubic-Schneider, Tina, London, Anne Serdakowski, Tschantz, William R, Kurz, Markus, Nguyen, Duc, Bourret, Aaron, Meyer, Matthew J, Faris, Jason E, Janatpour, Mary J, Chan, Vivien W, Yoder, Nicholas C, Catcott, Kalli C, McShea, Molly A, Sun, Xiuxia, Gao, Hui, Williams, Juliet, Hofmann, Francesco, Engelman, Jeffrey A, Ettenberg, Seth A, Sellers, William R, Lees, Emma

“…Despite an improving therapeutic landscape, significant challenges remain in treating the majority of patients with advanced ovarian or renal cancer. We…”
Get more information

Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates by Catcott, Kalli C, McShea, Molly A, Bialucha, Carl Uli, Miller, Kathy L, Hicks, Stuart W, Saxena, Parmita, Gesner, Thomas G, Woldegiorgis, Mikias, Lewis, Megan E, Bai, Chen, Fleming, Michael S, Ettenberg, Seth A, Erickson, Hans K, Yoder, Nicholas C

“…Antibody-drug conjugates (ADCs) are of great interest as targeted cancer therapeutics. Preparation of ADCs for early stage screening is constrained by…”
Get full text

Synthesis and characterization of Se-adenosyl-L-selenohomocysteine selenoxide by Duclos, Richard I., Cleary, Dillon C., Catcott, Kalli C., Zhou, Zhaohui Sunny

“…Selenium is an essential micronutrient in humans due to the important roles of the selenocysteine-containing selenoproteins. Organoselenium metabolites are…”
Get full text

Abstract 5810: The impact of scaffold, linker, homogeneity and payload selection on the efficacy and tolerability of anti-tubulin ADCs by Collins, Scott D., Keirstead, Natalie, Damelin, Marc, Toader, Dorin, Ishida, Katsu, Kumar, Niyanta N., Lancaster, Kelly L., Catcott, Kalli C., Yau, Annika, Bala, Mohan, Lowinger, Timothy B.

“…Abstract Antibody-drug conjugates (ADCs) achieve targeted drug delivery to a tumor and have demonstrated clinical success in many tumor types. The properties…”
Get full text

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity by Duvall, Jeremy R., Bukhalid, Raghida A., Cetinbas, Naniye M., Catcott, Kalli C., Slocum, Kelly, Avocetien, Kenneth, Bentley, Keith W., Bradley, Stephen, Clardy, Susan, Collins, Scott D., Ditty, Elizabeth, Eitas, Timothy, Jones, Brian D., Kelleher, Eugene W., Lee, Winnie, Monnell, Travis, Mosher, Rebecca, Protopopova, Marina, Qin, LiuLiang, Shaw, Pamela, Ter-Ovanesyan, Elena, Thomas, Joshua D., Wongthida, Phonphimon, Xu, Ling, Yang, Liping, Zurita, Jeffrey, Toader, Dorin, Damelin, Marc, Lowinger, Timothy B.

“…Abstract STING pathway agonism has emerged as a potential therapeutic mechanism to stimulate an innate anti-tumor immune response. However, the systemic…”
Get full text

Abstract P167: Site-specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios by Catcott, Kalli C., Clardy, Susan, Sadowsky, Jack, Rowntree, Rebecca K., Centibas, Naniye Malli, Xu, Ling, Polson, Andy, Avocetien, Kenneth, Carter, Tyler, Nazzaro, Mark, Kim, Dokyong "DK", Pillow, Thomas H., Zacharias, Neelie, Wu, Cong, Zurita, Jeffrey, Ditty, Elizabeth, Bradley, Stephen, Uttard, Alex, Du, Bingfan, Sawyer, William S., Leipold, Doug, Phillips, Gail Lewis, Qin, LiuLiang, Slocum, Kelly, Rosario, Geoffrey Del, Li, Ginny, Yu, Shang-Fan, Lee, David, Iyengar, Radha, Damelin, Marc, Toader, Dorin, Lowinger, Timothy B.

“…Abstract Key defining attributes of an antibody-drug conjugate (ADC) include the choice of targeting antibody, linker, and the drug-to-antibody ratio (DAR)…”
Get full text

Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma by Fessler, Shawn, Dirksen, Anouk, Collins, Scott D., Xu, Ling, Lee, Winnie, Wang, Jason, Eydelloth, Ron, Ter-Ovanesyen, Elena, Zurita, Jeffrey, Ditty, Elizabeth, Nehilla, Barrett, Clardy, Susan, Carter, Tyler, Avocetien, Kenneth, Nazzaro, Mark, Le, Nam, Catcott, Kalli C., Uttard, Alex, Du, Bingfan, Chin, Chen-Ni, Mosher, Rebecca, Slocum, Kelly, Qin, Liuliang, Lee, David, Toader, Dorin, Damelin, Marc, Lowinger, Timothy B.

“…Abstract The Dolasynthen platform incorporates the highly potent anti-mitotic agent auristatin F-HPA (AF-HPA), with its associated DolaLock mechanism of…”
Get full text

Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines by Bukhalid, Raghida A., Duvall, Jeremy R., Cetinbas, Naniye Malli, Catcott, Kalli C., Avocetien, Kenneth, Bentley, Keith W., Bradley, Stephen, Carter, Tyler, Chin, Chen-Ni, Clardy, Susan, Collins, Scott D., Eitas, Timothy, Jones, Brian D., Kelleher, Eugene W., Mosher, Rebecca, Nazzaro, Mark, Protopopova, Marina, Shaw, Pamela, Slocum, Kelly, Ter-Ovanesyan, Elena, Qin, LiuLiang, Thomas, Joshua D., Xu, Ling, Yang, Liping, Zurita, Jeffrey, Toader, Dorin, Damelin, Marc, Lowinger, Timothy B.

“…Abstract STING pathway agonism has emerged as a potential therapeutic mechanism to stimulate an innate anti-tumor immune response. While in principle systemic…”
Get full text

Abstract 2114: Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potent anti-tumor activity by delivering STING agonist specifically to tumor cells andFcγRI-expressing subset of myeloid cells by Cetinbas, Naniye Malli, Catcott, Kalli C., Monnell, Travis, Soomer-James, Jahna, Bentley, Keith, Clardy, Susan, Du, Bingfan, Kelleher, Eoin, Protopopova, Marina, Stevenson, Cheri, Thomas, Joshua D., Uttard, Alex, Toader, Dorin, Duvall, Jeremy, Bukhalid, Raghida, Damelin, Marc, Lowinger, Timothy B.

“…Abstract STING pathway agonism has emerged as a potential therapeutic strategy to stimulate anti-tumor immune responses. We have previously shown that tumor…”
Get full text

Abstract 2974: Targeting cadherin-6 (CDH6) with an antibody-drug conjugate for the treatment of ovarian and renal cancer by Collins, Scott D., Saxena, Parmita, Li, Xiao Y., Shim, Yeonju, Ostrom, Lance, Yoder, Nicholas C., Catcott, Kalli C., McShea, Molly A., Sun, Xiuxia, Bilic, Sanela, Tschantz, William R., Flaherty, Meghan, Mansfield, Keith, Hu, Tiancen, Capka, Vladimir, Kurz, Markus, Liric Rajlic, Ivana, Serdakowski London, Anne, Nguyen, Duc, Mosher, Rebecca, Meyer, Matthew J., Bourret, Aaron, Saeh, Jamal, Cameron, Scott, Lees, Emma, Bialucha, Carl U.

“…Abstract In an attempt to mine tumor versus normal mRNA expression datasets for novel tumor antigens, we identified the Cadherin-6 (CDH6) gene as frequently…”
Get full text

Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab by Duvall, Jeremy R., Bukhalid, Raghida A., Cetinbas, Naniye M., Catcott, Kalli C., Lancaster, Kelly, Bentley, Keith W., Clark, Suzanna, Clardy, Susan, Collins, Scott D., Dirksen, Anouk, Ditty, Elizabeth, Du, Bingfan, Kelleher, Eugene W., Monnell, Travis, Protopopova, Marina, Routhier, Caitlin, Stevenson, Cheri, Ter-Ovanesyan, Elena, Thomas, Joshua D., Uttard, Alex, Wang, Jason, Wongthida, Phonphimon, Xu, Ling, Yau, Annika, Zurita, Jeffrey, Toader, Dorin, Damelin, Marc, Lowinger, Timothy B.

“…Abstract We present here a novel therapeutic agent, XMT-2056, that results in robust anti-tumor activity mediated by an immune response through targeted…”
Get full text

Abstract 5442: Microscale methods for preparation and screening of antibody-drug conjugates by Yoder, Nicholas C., Catcott, Kalli C., McShea, Molly A., Bialucha, Carl Uli, Saxena, Parmita, Bai, Chen, Miller, Kathy L., Gesner, Thomas G., Woldegiorgis, Mikias, Hicks, Stuart W., Lewis, Megan E., Fleming, Michael S., Erickson, Hans K., Ettenberg, Seth E., Keating, Thomas A.

“…Abstract Antibody-drug conjugates (ADCs) are hybrid biotherapeutics that combine the targeting specificity of monoclonal antibodies with chemically conjugated,…”
Get full text

Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates by Catcott, Kalli C., McShea, Molly A., Bialucha, Carl Uli, Miller, Kathy L., Hicks, Stuart W., Saxena, Parmita, Gesner, Thomas G., Woldegiorgis, Mikias, Lewis, Megan E., Bai, Chen, Fleming, Michael S., Ettenberg, Seth A., Erickson, Hans K., Yoder, Nicholas C.

“…Antibody-drug conjugates (ADCs) are of great interest as targeted cancer therapeutics. Preparation of ADCs for early stage screening is constrained by…”
Get full text